Exelixis Inc Increase (Decrease) in Employee Related Liabilities
Exelixis Inc (EXEL) reported Increase (Decrease) in Employee Related Liabilities of -$429.00 thousand for the 9-month period ending 2019-09-27, per its 10-Q filed 2019-10-30.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities · last filed 2019-10-30
- Exelixis Inc increase (decrease) in employee related liabilities for the quarter ending 2019-09-27 was $7.57M, a 31.75% increase year-over-year.
- Exelixis Inc increase (decrease) in employee related liabilities for the quarter ending 2019-06-28 was $1.59M, a 103.84% increase year-over-year.
- Exelixis Inc increase (decrease) in employee related liabilities for the quarter ending 2019-03-29 was -$9.59M.
- Exelixis Inc increase (decrease) in employee related liabilities for the quarter ending 2018-12-28 was $4.86M, a 319.24% increase year-over-year.
- Exelixis Inc increase (decrease) in employee related liabilities for fiscal 2018 was $11.07M, a 1397.83% increase from fiscal 2017.
- Exelixis Inc increase (decrease) in employee related liabilities for fiscal 2017 was $739.00K, a 95.58% decline from fiscal 2016.
- Exelixis Inc increase (decrease) in employee related liabilities for fiscal 2016 was $16.70M.
- Exelixis Inc increase (decrease) in employee related liabilities for fiscal 2016 was $16.70M, a 5887.46% increase from fiscal 2016.
| Period end | Increase (Decrease) in Employee Related Liabilities 3 month | Increase (Decrease) in Employee Related Liabilities 6 month | Increase (Decrease) in Employee Related Liabilities 9 month | Increase (Decrease) in Employee Related Liabilities 12 month |
|---|---|---|---|---|
| 2019-09-27 | $7.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $9.16M derived: sum of 2 quarters · filed 2019-10-30 | -$429.00K 10-Q · filed 2019-10-30 | $4.43M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-06-28 | $1.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$8.00M 10-Q · filed 2019-07-31 | -$3.14M derived: sum of 3 quarters · filed 2019-07-31 | $2.61M derived: sum of 4 quarters · filed 2019-10-30 |
| 2019-03-29 | -$9.59M 10-Q · filed 2019-05-01 | -$4.73M derived: sum of 2 quarters · filed 2019-05-01 | $1.01M derived: sum of 3 quarters · filed 2019-10-30 | $1.79M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-12-28 | $4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $10.60M derived: sum of 2 quarters · filed 2019-10-30 | $11.39M derived: sum of 3 quarters · filed 2019-10-30 | $11.07M 10-K · filed 2019-02-22 |
| 2018-09-28 | $5.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-30 | $6.53M derived: sum of 2 quarters · filed 2019-10-30 | $6.21M 10-Q · filed 2019-10-30 | $7.37M derived: sum of 4 quarters · filed 2019-10-30 |
| 2018-06-29 | $782.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $465.00K 10-Q · filed 2019-07-31 | $1.62M derived: sum of 3 quarters · filed 2019-07-31 | $5.98M derived: sum of 4 quarters · filed 2019-07-31 |
| 2018-03-30 | -$317.00K 10-Q · filed 2019-05-01 | $842.00K derived: sum of 2 quarters · filed 2019-05-01 | $5.20M derived: sum of 3 quarters · filed 2019-05-01 | |
| 2017-12-29 | $1.16M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $5.52M derived: sum of 2 quarters · filed 2019-02-22 | $739.00K 10-K · filed 2019-02-22 | |
| 2017-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | -$420.00K 10-Q · filed 2017-11-01 | ||
| 2017-09-29 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $5.42M derived: sum of 2 quarters · filed 2018-11-01 | -$420.00K 10-Q · filed 2018-11-01 | $3.93M derived: sum of 4 quarters · filed 2018-11-01 |
| 2017-06-30 | $1.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$4.78M 10-Q · filed 2017-08-02 | -$431.00K derived: sum of 3 quarters · filed 2018-05-02 | $5.25M derived: sum of 4 quarters · filed 2018-05-02 |
| 2017-03-31 | -$5.84M 10-Q · filed 2017-05-01 | -$1.50M derived: sum of 2 quarters · filed 2018-05-02 | $4.18M derived: sum of 3 quarters · filed 2018-05-02 | $8.45M derived: sum of 4 quarters · filed 2018-05-02 |
| 2016-12-31 | $4.35M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $10.03M derived: sum of 2 quarters · filed 2017-11-01 | $14.29M derived: sum of 3 quarters · filed 2017-11-01 | $16.70M 10-K · filed 2017-02-27 |
| 2016-12-30 | $16.70M 10-K · filed 2019-02-22 | |||
| 2016-09-30 | $5.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $9.94M derived: sum of 2 quarters · filed 2017-11-01 | $12.36M 10-Q · filed 2017-11-01 | |
| 2016-06-30 | $4.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $6.68M 10-Q · filed 2017-08-02 | ||
| 2016-03-31 | $2.41M 10-Q · filed 2017-05-01 | |||
| 2016-01-01 | $279.00K 10-K · filed 2018-02-26 | |||
| 2015-12-31 | $279.00K 10-K · filed 2017-02-27 | |||
| 2014-12-31 | -$9.45M 10-K · filed 2017-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |